On this July 4th, we at Capsida Biotherapeutics take a moment to honor the historical significance of this day. In 1776, the Continental Congress adopted the Declaration of Independence, marking the birth of the United States—a nation built on the principles of freedom, equality, and the pursuit of happiness. Wishing everyone a reflective and joyful Independence Day! #IndependenceDay2024 #CapsidaBiotherapeutics #Freedom #Innovation #July4th
Capsida Biotherapeutics
Biotechnology
Newbury Park, CA 12,777 followers
Engineering novel AAVs and developing the next generation of gene therapies
About us
Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders. Capsida's technology allows for the targeted penetration of cells and organs, while limiting collateral impact on non-targeted cells and organs, especially the liver. This technology allows for the delivery of the gene therapy in a non-invasive way through intravenous administration. Capsida's technology is protected by a growing intellectual property portfolio which includes more than 30 patent applications and one issued U.S. patent 11,149,256. The company is exploring using the technology across a broad range of life-threatening genetic disorders. Its initial pipeline consists of multiple neurologic disease programs. The company has strategic collaborations with AbbVie and CRISPR, which provide independent validation of Capsida's technology and capabilities. Capsida is a multi-functional and fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, multi-modality cargo development and optimization, translational biology, process development and state-of-the-art manufacturing, and broad clinical development experience. Capsida's biologically driven, high-throughput AAV engineering and cargo optimization platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at the California Institute of Technology.
- Website
-
http://www.capsida.com
External link for Capsida Biotherapeutics
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Newbury Park, CA
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Biotechnology, AAV Engineering, Gene Therapy, Biopharmaceuticals, Protein Engineering, Analytical Development, Process Development, and AAV Immunology
Locations
-
Primary
1290 Rancho Conejo Blvd
Newbury Park, CA 91320, US
Employees at Capsida Biotherapeutics
Updates
-
At Capsida, we're passionate about innovation and dedicated to our mission, but we also understand the importance of work-life balance. As part of our commitment to our team's well-being and to celebrate Independence Day, Capsida will be closed for the entire week of July 4th. This break reflects our culture, which values and supports each team member's need for rest, relaxation, and time spent with loved ones. #CapsidaBiotherapeutics #WorkLifeBalance #IndependenceDay2024 #CompanyCulture
-
-
Congratulation to Capsida’s Chakameh Azimpour, Ph.D., who has contributed to a groundbreaking analytical development position paper published by the EFPIA - European Federation of Pharmaceutical Industries and Associations). This paper focuses on the use of Next Generation Sequencing (#NGS) for Adventitious Virus Detection in Biological Medicinal Products. The publication is a collaborative effort among leading experts across the industry, providing key insights and recommendations aimed at scientists and regulatory specialists. Read the full paper here: EFPIA Position Paper https://bit.ly/3XHmVV9 #CapsidaBio #EFPIA #Biotech #NGS #ScienceCommunication
-
-
We are excited to have been selected to give an oral presentation in the upcoming GBA1 GCAN Meeting, hosted by McGill University. On June 29th Kimberly McDowell, Ph.D., presents our research entitled: “Systemic AAV Gene Therapy with CNS-Targeted Engineered Capsids Achieves Significant GCase Activity Increases in the Primate Brain to Support the Potential Treatment of PD-GBA1” This presentation will showcase our latest advancements in gene therapy, highlighting the potential to make a significant impact on the treatment of Parkinson’s disease associated with GBA1 mutations. 📅 Date: June 29, 2024 🌐 Event Website: GBA1 GCAN Meeting #GeneTherapy #GBA-PD #ParkinsonsDisease
-
-
For this year’s Pride Parade, our team came together to show support and celebrate the vibrant spirit of the LGBTQ+ community. Thank you to everyone who joined us and made this event unforgettable. Your energy and enthusiasm truly made the day special! #Pride2024 #CapsidaCelebrates #biotech
-
Today, we celebrate Juneteenth, a pivotal moment in American history that marks the end of slavery in the United States. As we reflect on this important day, we celebrate the progress made and remain dedicated to the ongoing fight for equality and justice for all. #Juneteenth #Capsida #Diversity #CelebrateFreedom
Juneteenth
nmaahc.si.edu
-
Capsida’s Chakameh Azimpour, Ph.D will be presenting a poster at the 2024 PDA Advanced Therapy Medicinal Products Conference: 📅 Date: 24-25 June 2024 📍 Location: Amsterdam, The Netherlands The poster, entitled "Development of a dual reporter cargo and systemic incorporation of a highly flexible, benchtop automation system to facilitate rAVV9 based novel capsid development and characterization," showcases innovative research that highlights the breadth of Capsida’s analytical development expertise in characterizing novel engineered capsids. This work is a collaborative effort by a talented team of Capsida researchers: Paul Denis, Kevin Chu, Jesse Granados, Regan Sobaje, Claire S., Leandro Fernandez, Tiffany Morrison, Lysa-Anne Volpe, Chakameh Azimpour, Ph.D. Well done to the whole team! #AdvancedTherapies #PDAConference #CapsidDevelopment #BiotechInnovation #ScientificResearch #AutomationInScience #GeneTherapy #ATMP #AdvancedTherapyMedicinalProduct
-
-
Capsida’s David Goertsen, Ph.D., will be presenting at the 4th Next Generation Gene Therapy Vectors Summit, focused on Innovating Gene Therapy Capsid & Payload Design. Dr. Goertsen’s presentation will review Capsida’s progress in AAV capsid engineering to develop gene therapy candidates with improved safety and efficacy profiles for PD-GBA and genetic epilepsy due to STXBP1: • Platform advancements leading to breakthrough, IV-delivered engineered AAV capsids for the CNS • Generations of directed evolution yielding highly targeted AAV capsids with increased therapeutic index • Potential for Capsida's engineered AAVs to treat neurological disorders across all age groups This summit brings together more than 60 biopharma leaders, service providers, and academic pioneers to discuss the latest advancements and innovations in vector development for gene therapies. 📅 Event: 4th Next Generation Gene Therapy Vectors Summit 📍 Location: Boston 🗓️ Date: June 14 at 2:15pm #GeneTherapy #AAV #Biopharma #Capsida #Innovation #NextGenVectorsSummit #NeurologicalDisorders #R&D
-
-
Great to be at BIO 2024! #BIO2024 #Genetherapy #CapsidaBiotherepeutics
-